ClinicalTrials.gg
CompletedNCT05549492Updated Sep 22, 2022

Transversus Abdominis Plane Block With or Without Buprenorphine After Inguinal Hernia Surgery

A Phase 1 interventional study of Ropivacaine 0.25%-NaCl 0.9% Injectable Solution in Inguinal Hernia and Pain, Postoperative, sponsored by Egymedicalpedia. Completed at 1 site in Egypt. Open to participants aged 30 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-09-22.

Sponsored by Egymedicalpedia · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jan 2021, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
30 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Hernia, Inguinal with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Hernia, Inguinal · Egypt.

Enrollment
18th of 43
64 · median 60
Started
2021
with 2 others
Phase 1
3 of 45
none open now
Registered
13th of 45
by date
Lead sponsor
2 of 45
Egymedicalpedia

Among the 45 studies in Hernia, Inguinal with a site in Egypt, this one is the 18th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2021, is one of 3 in phase 1, and was the 13th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

16 of the 45 studies in Hernia, Inguinal with a site in Egypt are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 30 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernia, Inguinal with a site in Egypt, or all of them as a file.
02

Study summary

Buprenorphine intravenous, sublingual, and transdermal patches have been researched for their antihyperalgesic effects, although peripherally mediated effects have not been examined in Egypt surprisingly

Read the detailed description

This prospective, randomized, double-blind controlled trial involved 88 patients who were scheduled for inguinal hernia surgery followed by a TAP block. Patients were allocated into group B (n= 44) received 20 ml of 0.25% Ropivacaine for TAP block; group BR (n= 44) received 20 ml of 0.25% Ropivacaine containing 300 μg of buprenorphine for TAP Block. The primary outcome of the study was the analgesic and antihyperalgesic effect of buprenorphine compared to the control group. The duration of analgesia, analgesic consumption, postoperative pain scores at rest and sitting up to 48 hrs, and effect on wound hyperalgesia at 24 and 48 hrs were evaluated. Secondary outcomes of the study include incidence of side effects and TAP block-related complications were recorded. Effect of buprenorphine on patients with predicted high pain scores and incidence of persistent postoperative pain were also determined.

A transversus abdominis plane (TAP) block provides analgesia of the anterior and lateral abdominal wall below the umbilicus by blocking the T6-L1 segmental nerves as they lie within the fascial plane between the transversus abdominis and internal oblique muscles: bilateral block for midline abdominal incision. It was first described in 2001 by Rafi as a traditional blind landmark technique using the lumbar triangle of Petit. Local anesthetic is then injected between the internal oblique and transverse abdominis muscles just deep the fascial plane, the plane through which the sensory nerves pass

03

Conditions studied

  • Inguinal Hernia
  • Pain, Postoperative
04

Who can participate

Ages eligible
30 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with Inguinal Hernia
  2. Medically free

Exclusion criteria

Exclusion Criteria:

  1. participants with a history of heart, renal and liver cell failure.
  2. allergic reaction to studied drugs, and history of epilepsy,
  3. hydrodynamic instability,
  4. chronic pain.
  5. mental illness.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Group B

    Candidates received 20 ml of 0.25% ropivacaine for TAP block

    Drug: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution

  • Experimental
    Group RB

    Candidates received 20 ml of 0.25% ropivacaine and 300 μg of buprenorphine, respectively, for the TAP block.

    Drug: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution

Interventions

  • The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means "no pain" and 10 means "the worst pain" as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.

    Also known as: buprenorphine 300 μg

06

What researchers measure

Primary outcomes

  1. Post Operative Pain

    The pain level of the cases is evaluated by means of the digital pain as the 11-point visual analog scale (VAS) whereas 0-Represents no pain, 10 - Worst imaginable pain), as well as the 11-point VAS-A (0-Represents no anxiety, 10 - Highest anxiety)

    Time frame: 2 hours after the operation upto 48-hour analgesic after surgery

07

Study locations

1 site
  • October 6 University Hospital
    Giza, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in May 2022, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2022
First posted
Sep 22, 2022
StartActual
Jan 1, 2021
Primary completionActual
May 1, 2022
CompletionActual
May 30, 2022
Last update
Sep 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05549492
Lead sponsor
Egymedicalpedia
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Jan 1, 2021
Primary completion
May 1, 2022
Completion
May 30, 2022
Last update
Sep 22, 2022

Study contacts

Nirvana Elshalakany, Professor
principal investigator · Department of Anesthesia and I.C.U. faculty of Medicine October six university, Egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion